Generic Medicines in India

• India’s generic medicines are affordable and bioequivalent to branded drugs, yet their reliability is constrained by a decentralized regulatory framework and persistent quality control gaps, affecting equitable healthcare access.

Status of Generic Medicines in India

• Global Supply: India provides ~20% of global generics and 40% of U.S. generics.
• Export Growth: Pharmaceutical exports reached US$27.9 billion in FY24, a 10% rise from FY23.
• PMBJP Reach: 15,000 Jan Aushadhi Kendras offer ~2,047 drugs and 300 surgical items at 50–80% lower prices.
• Consumer Savings: PMBJP saved patients approximately ₹30,000 crore over the past decade.
• Market Size: India’s generics market is US$50 billion, projected to reach US$130 billion by 2030.

Need for Generic Medicines

• Affordable: Generics provide cost-effective alternatives to branded drugs, addressing healthcare affordability in a population with income disparities.
• Global Supplier: India’s low production costs and economies of scale enable it to supply affordable medicines both domestically and globally.
• Reduced Burden: Generic medicines help reduce out-of-pocket healthcare expenses, which accounted for 39.4% of total health expenditure in 2021-22.
• Government Initiatives: Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, generics worth ₹5,600 crore sold in a decade saved consumers approximately ₹30,000 crore by August 2024.

Issues with Generic Medicines

• Bioequivalence Variability: Generics often differ in excipients and manufacturing processes, impacting therapeutic efficacy and safety.
• Therapeutic Inefficacy: A PGIMER study showed innovator drugs had better therapeutic outcomes than generics. E.g., itraconazole’s efficacy was 73% for innovator drugs versus 29% for generics.
• Manufacturing Gaps: Variations in excipients, compression forces, and tablet properties lead to inconsistent drug absorption and bioavailability.
• Bioequivalence Thresholds: Regulatory limits (80%-125% for pharmacokinetics) may not be suitable for drugs with narrow therapeutic indexes, risking subtherapeutic or adverse effects.
• Stability Concerns: Inadequate enforcement of stability testing, especially under diverse climatic conditions, reduces drug reliability.
• Impurity Levels: India’s pharmacopoeia permits higher impurity levels than U.S. and EU standards, compromising safety.

Challenges Faced by Generic Medicines in India

• Perception Gap: About 35% of patients view generics as less effective than branded drugs, affecting adoption (PMC).
• Brand Loyalty: Strong consumer and physician preference for branded medicines discourages switching to generics.
• Trust Deficit: Substandard or counterfeit drugs. E.g., contaminated Indian cough syrups causing fatalities abroad, erode confidence.
• Distribution Challenges: 3.16% of sampled medicines were substandard and rural access remains limited due to infrastructure gaps.
• Patent Constraints: Intense competition reduces profitability, and patent/evergreening issues delay generic entry.

Way Forward

• Expand PMBJKs: Increase PMBJK stores to reach more people with 2,000+ low-cost generics.
• Use Digital Tools: Apps like Janaushadhi Sugam help compare prices and locate stores, making buying easier.
• Ensure Quality: Follow revised GMP and bioequivalence rules to maintain safe, reliable generics.
• Give Incentives: Offer ₹2 lakh support for PMBJKs in rural and remote areas to expand access (PIB).
• Promote Generic Prescribing: Encourage doctors to prescribe by generic names to cut costs for patients.
• Raise Awareness: Conduct campaigns like Jan Aushadhi Diwas to build trust and educate citizens on benefits.

India, often called the “Pharmacy of the World”, plays a vital role in supplying affordable generics globally, yet quality, trust, and access challenges hinder their full potential domestically. Stronger regulation, wider PMBJK reach, and public awareness can make generics a reliable pillar of universal healthcare.

Reference: The Hindu

Foundation Courses

PMF IAS Pathfinder for Mains – Question 361

Q. Despite being cost-effective and bioequivalent, generic medicines in India continue to face challenges of regulatory oversight and quality assurance. Critically examine their role in ensuring equitable healthcare access. (250 Words) (15 Marks)

Approach

• Introduction: Provide a contextual introduction to generic medicine in India, highlighting its global share and domestic demand.
• Body: Examine the role of generic medicine in ensuring equitable healthcare access, challenges and the way forward to overcome these challenges.
• Conclusion: Emphasis on affordable and accessible healthcare through bridging regulatory gaps and enhancing outreach.